ReviewTherapeutic innovation & regulatory science2023

A Structured Benefit-Risk Assessment Operating Model for Investigational Medicinal Products in the Pharmaceutical Industry.

Tim Sullivan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.